| 1 | The Putative Drp1 Inhibitor mdivi-1 Is a Reversible Mitochondrial Complex I Inhibitor that Modulates Reactive Oxygen Species. (Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V, Cherok E, Khalil A, Yadava N, Ge SX, Francis TC, Kennedy NW, Picton LK, Kumar T, Uppuluri S, Miller AM, Itoh K, Karbowski M, Sesaki H, Hill RB, Polster BM) Dev Cell 2017 03 27;40(6):583-594.e6 150 Citations |
| 1 | Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles. (Tanner MJ, Wang J, Ying R, Suboc TB, Malik M, Couillard A, Branum A, Puppala V, Widlansky ME) Am J Physiol Heart Circ Physiol 2017 Mar 01;312(3):H515-H527 16 Citations |
| 1 | Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. (Gui J, Gober M, Yang X, Katlinski KV, Marshall CM, Sharma M, Werth VP, Baker DP, Rui H, Seykora JT, Fuchs SY) J Invest Dermatol 2016 10;136(10):1990-2002 13 Citations |
| 1 | Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells. (Cunniff B, Benson K, Stumpff J, Newick K, Held P, Taatjes D, Joseph J, Kalyanaraman B, Heintz NH) J Cell Physiol 2013 Apr;228(4):835-45 30 Citations |
| 1 | Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. (Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV) Circ Cardiovasc Interv 2012 Jun;5(3):347-56 26 Citations |
